BHM Stock Overview
Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Bachem Holding AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF8.15 |
| 52 Week High | CHF9.50 |
| 52 Week Low | CHF5.04 |
| Beta | 0.69 |
| 1 Month Change | 3.69% |
| 3 Month Change | 61.39% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 1.44% |
Recent News & Updates
Recent updates
Shareholder Returns
| BHM | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -1.2% | -9.9% | -2.0% |
| 1Y | n/a | -14.9% | -0.3% |
Return vs Industry: Insufficient data to determine how BHM performed against the German Life Sciences industry.
Return vs Market: Insufficient data to determine how BHM performed against the German Market.
Price Volatility
| BHM volatility | |
|---|---|
| BHM Average Weekly Movement | 18.5% |
| Life Sciences Industry Average Movement | 6.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: BHM's share price has been volatile over the past 3 months.
Volatility Over Time: BHM's weekly volatility has increased from 13% to 18% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1971 | 2,006 | Thomas Meier | www.bachem.com |
Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. The company engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). It also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services.
Bachem Holding AG Fundamentals Summary
| BHM fundamental statistics | |
|---|---|
| Market cap | €6.05b |
| Earnings (TTM) | €115.09m |
| Revenue (TTM) | €593.99m |
52.5x
P/E Ratio10.2x
P/S RatioIs BHM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BHM income statement (TTM) | |
|---|---|
| Revenue | CHF577.32m |
| Cost of Revenue | CHF400.35m |
| Gross Profit | CHF176.96m |
| Other Expenses | CHF65.10m |
| Earnings | CHF111.86m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Jul 25, 2024
| Earnings per share (EPS) | 1.49 |
| Gross Margin | 30.65% |
| Net Profit Margin | 19.38% |
| Debt/Equity Ratio | 0% |
How did BHM perform over the long term?
See historical performance and comparison